Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

This study is testing a combination of two cancer drugs — sacituzumab govitecan and zimberelimab — together with targeted brain radiation (stereotactic radiosurgery, or SRS) for people with triple-negative breast cancer that has spread to the brain. Triple-negative breast cancer is an aggressive form that has limited treatment options, and brain metastases are a serious complication. **You may be eligible if...** - You are 18 or older with confirmed triple-negative breast cancer - Your cancer has spread to the brain (confirmed by MRI or surgery) - You are eligible for stereotactic radiosurgery (SRS) to brain tumors - The largest brain tumor is 4 cm or smaller in diameter - Your general health status allows treatment (ECOG 0–2) - You have previously received taxane-based chemotherapy with anthracyclines **You may NOT be eligible if...** - Your brain tumors are too large or too numerous for SRS - You have uncontrolled or very symptomatic brain tumors not manageable with low-dose steroids - You are pregnant or not willing to use contraception - You do not meet blood count or organ function requirements Talk to your doctor to see if this trial is right for you.